← Back to headlines
Mirum Pharmaceuticals Reports Positive Phase 2b Data for Volixibat
Mirum Pharmaceuticals (MIRM) announced positive Phase 2b data for its drug Volixibat in patients with Primary Sclerosing Cholangitis (PSC) at the EASL Congress.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
